We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.


Download Mobile App
Recent News COVID-19 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology BioResearch Industry

SARS-CoV-2 Test Uses Innovative Digital Microfluidics Technology for Accurate RT-PCR Testing with Rapid Turn-Around Time

By LabMedica International staff writers
Posted on 07 Apr 2021
A new RT-PCR test uses innovative digital microfluidics (DMF) technology for the qualitative detection of RNA from the SARS-CoV-2 virus in nasopharyngeal and nasal swab specimens within 17 minutes.

Baebies (Durham, NC, USA) has received acknowledgement from the US Food & Drug Administration (FDA) for the company’s Emergency Use Notification (EUN) for an RT-PCR test to detect SARS-CoV-2 on its FINDER 1.5 Instrument. The company’s FINDER SARS‑CoV-2 Test is intended for the qualitative detection of RNA from the SARS-CoV-2 virus in nasopharyngeal and nasal swab specimens with RT-PCR performed within 17 minutes.

Image: FINDER 1.5 Instrument (Photo courtesy of Baebies)
Image: FINDER 1.5 Instrument (Photo courtesy of Baebies)

The FINDER 1.5 platform includes a toaster-sized instrument and disposable single-use cartridge and features a small footprint at just 8 inches wide with a commercial tablet interface, easy and intuitive workflow, and DMF technology, which minimizes sample and reagent volumes. The underlying DMF technology is a method to programmably manipulate tiny droplets of liquid by electrical control of surface tension on a disposable cartridge. Baebies’ DMF technology is protected by several hundred patents. Digital microfluidics supports multifunctional assay methods – including molecular, immunoassay, and chemistry – on the same cartridge. Baebies recently won the 2020 AACC Disruptive Technology Award for FINDER in a competition emerging as the next innovative testing solution that will transform patient care.

“Our FINDER SARS-CoV-2 test combines the accuracy of RT-PCR testing with a rapid turn-around time, which is made possible by our innovative digital microfluidics technology,” said Richard West, Co-Founder and Chief Executive Officer of Baebies. “We are launching the FINDER 1.5 Instrument and FINDER SARS-CoV-2 Test to address the continued need for access to fast and accurate testing in health care facilities with high complexity laboratories.”

“In development of our FINDER SARS-CoV-2 Test, we focused on accelerating RT-PCR and sample processing for rapid results through several innovations – all made possible by digital microfluidics,” added Vamsee Pamula, co-founder and President. “This technology powers both our diagnostic platform, FINDER, and FDA-authorized newborn screening platform, SEEKER. Baebies’ core focus still remains neonatal and pediatric diagnostics, however, the current COVID-19 pandemic doesn’t distinguish between children and adults – everyone is at risk.”

Related Links:

Latest COVID-19 News